Dr Anjana Kulkarni

Transparency under the CMA Order 2014

All private healthcare operators are required under the Competition and Markets Authority Order 2014 (“The CMA Order”) to be transparent about the relationship between their doctor and the private healthcare operator. Therefore, prospective patients should be aware that (in addition to being permitted to consult with and to treat patients at our facilities) this doctor also has an advisory role with HCA UK and is paid by HCA UK for this advisory role. We describe the nature of the role below, and we indicate how much the doctor has been paid for performing the role since 1 January 2023

Dr Kulkarni provides medical advisory services to HCA, including acting as the Clinical Geneticist for the HCA Genomics Review Board.

In this role, she also provides expert guidance regarding germline genetic testing for hereditary cancers. She advises on the development of clinically appropriate genetic pathways for HCA patients. She also provides clinical genetics input on the tumour boards for HCA.

HCA UK is charged by doctors in return for their expertise and advice, including on how to operate safe hospital facilities delivering complex care. All services provided under this agreement are charged to HCA. In 2023 the total paid for these services was £41,082.

If a doctor provides HCA UK with medical advisory services and also practises in the NHS, HCA UK requires that doctor to attest that he/she is not compromising his/her NHS commitments in so doing.